Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. META
5. SPY
6. ACN
7. IBM
8. PRIM
9. PFE
10. TSLA

Go back to Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

Edgewise Therapeutics (EWTX) PT Raised to $52 at Leerink

June 16, 2026 1:08 PM EDT

Leerink analyst Joseph Schwartz raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $50.00) while maintaining a Outperform rating.

The analyst comments "We continue to think that CIRRUS Part D checks the key boxes for EDG-7500 across obstructive (oHCM) and non-obstructive... More